

Gonococcal Isolate Surveillance Project (GISP) Table California, 2017

- Isolates by Type of Resistance, California Sites, 2013–2017

Gonococcal Isolate Surveillance Project (GISP), Isolates by Type of Resistance, California Sites, 2013–2017

CLINIC SITE	2013	2013	2014	2014	2015	2015	2016	2016	2017	2017
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
TOTALS										
Total Specimens	763		860		816		868		866	
No Resistance	351	46.0	428	49.8	358	43.9	387	44.6	338	39.0
Ceftriaxone Decreased Susceptibility ¹	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cefixime Decreased Susceptibility ²	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0
Azithromycin Decreased Susceptibility ³	4	0.5	5	0.6	9	1.1	32	3.7	29	3.3
Ciprofloxacin Decreased Susceptibility ⁴	7	0.9	9	1.0	16	2.0	7	0.8	10	1.2
Ciprofloxacin-Resistant ⁵	272	35.6	260	30.2	246	30.1	313	36.1	391	45.2
Other Drug Resistance*	330	43.3	338	39.3	369	45.2	337	38.8	310	35.8
Los Angeles										
Total Specimens	194		171		81		133		199	
No Resistance	91	46.9	92	53.8	43	53.1	51	38.3	78	39.2
Ceftriaxone Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cefixime Decreased Susceptibility	0	0.0	0	0.0	0	0.0	1	0.8	0	0.0
Azithromycin Decreased Susceptibility	1	0.5	2	1.2	3	3.7	6	4.5	8	4.0
Ciprofloxacin Decreased Susceptibility	0	0.0	0	0.0	0	0.0	1	0.8	3	1.5
Ciprofloxacin-Resistant	67	34.5	43	25.1	18	22.2	59	44.4	85	42.7
Other Drug Resistance*	89	45.9	63	36.8	34	42.0	53	39.8	73	36.7
Orange										
Total Specimens	124		171		182		194		142	
No Resistance	47	37.9	82	48.0	86	47.3	79	40.7	62	43.7
Ceftriaxone Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cefixime Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Azithromycin Decreased Susceptibility	1	0.8	0	0.0	0	0.0	5	2.6	3	2.1
Ciprofloxacin Decreased Susceptibility	1	0.8	2	1.2	1	0.5	2	1.0	0	0.0
Ciprofloxacin-Resistant	55	44.4	52	30.4	53	29.1	74	38.1	62	43.7
Other Drug Resistance*	53	42.7	58	33.9	74	40.7	82	42.3	54	38.0
San Diego										
Total Specimens	176		218		189		195		195	
No Resistance	87	49.4	105	48.2	69	36.5	81	41.5	67	34.4
Ceftriaxone Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cefixime Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Azithromycin Decreased Susceptibility	1	0.6	0	0.0	1	0.5	3	1.5	2	1.0
Ciprofloxacin Decreased Susceptibility	6	3.4	6	2.8	2	1.1	2	1.0	3	1.5
Ciprofloxacin-Resistant	56	31.8	66	30.3	59	31.2	78	40.0	109	55.9
Other Drug Resistance*	67	38.1	98	45.0	102	54.0	91	46.7	63	32.3
San Francisco										
Total Specimens	269		300		364		346		330	
No Resistance	126	46.8	149	49.7	160	44.0	176	50.9	131	39.7
Ceftriaxone Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cefixime Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Azithromycin Decreased Susceptibility	1	0.4	3	1.0	5	1.4	18	5.2	16	4.8
Ciprofloxacin Decreased Susceptibility	0	0.0	1	0.3	13	3.6	2	0.6	4	1.2
Ciprofloxacin-Resistant	94	34.9	99	33.0	116	31.9	102	29.5	135	40.9
Other Drug Resistance*	121	45.0	119	39.7	159	43.7	111	32.1	120	36.4

¹ Minimum inhibitory concentration (MIC) ≥ 0.25 µg/mL; ² MIC ≥ 0.5 µg/mL; ³ MIC ≥ 2.0 µg/mL; ⁴ MIC 0.125 to 0.50 µg/mL; ⁵ MIC ≥ 1.0 µg/mL

* Other Drug Resistance includes penicillin and tetracycline.

Note: Totaling the types of resistance may add to more than total specimens, due to multi-drug-resistant specimens.

Source: Centers for Disease Control and Prevention, Gonococcal Isolate Surveillance Project, Sexually Transmitted Diseases Clinic Sites
California Department of Public Health, STD Control Branch